P-21 Peptide vs Thymalin
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
P-21 Peptide
Short neuropeptide based on the activity-dependent neurotrophic factor (ADNF) family with potent neuroprotective effects demonstrated in Alzheimer's disease models. Distinct from the cell cycle inhibitor protein p21/CDKN1A. Reduces amyloid-beta burden, improves cognitive outcomes in rodent models, and modulates neuroinflammation through STAT3 and JAK2 signaling pathways.
Full profileThymalin
Thymus-derived peptide bioregulator developed in Russia containing a mixture of low-molecular-weight peptides extracted from calf thymus. Primarily studied for reversing immunological aging (immunosenescence) and extending healthy lifespan. Vladimir Khavinson's longitudinal research on elderly patients links thymalin administration to significant improvements in immune markers and all-cause mortality reduction.
Full profile| P-21 Peptide | Thymalin | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | P21, Colivelin fragment, P21 neuropeptide, ADNF-related neuropeptide | thymic peptide bioregulator, T-activin extract, thymus peptide, thymic bioregulator |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 5mcg–20mcg mcg, daily or every other day (intranasal or SC) | 5mg–20mg mg, 5–10 day course, 1–2x per year |
| Administration | Intranasal, Subcutaneous injection | Intramuscular injection, Subcutaneous injection |
| Key side effects | Limited human safety data, In animal studies: well-tolerated at therapeutic doses, Theoretical STAT3 pathway concerns with chronic use (pro-survival signaling), Nasal irritation (intranasal route) | Injection site reactions, Mild fever (rare), Temporary increase in immune activity (desired response), Rare hypersensitivity |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: P-21 Peptide is preclinical only, while Thymalin is research-stage.
- Administration: P-21 Peptide — Intranasal, Subcutaneous injection; Thymalin — Intramuscular injection, Subcutaneous injection.
- Dosing units differ: P-21 Peptide is dosed in mcg, Thymalin in mg — they operate at different scales.
- Frequency: P-21 Peptide is typically daily or every other day (intranasal or SC); Thymalin is 5–10 day course, 1–2x per year.
How each works
P-21 Peptide
P-21 activates STAT3/JAK2 signaling through CNTF-related pathways, reducing amyloid-beta toxicity by activating amyloid-clearing enzymes (insulin-degrading enzyme, neprilysin) and inhibiting tau phosphorylation. Derived from the colivelin family of neuroprotective peptides, P-21 demonstrates cognitive improvement in Alzheimer's mouse models at doses far below cytotoxic levels. Human data remains limited.
Thymalin
Thymalin contains multiple bioactive peptides that stimulate T-lymphocyte differentiation and restore thymic function that declines with age. In Khavinson's 6-year controlled trial of elderly patients (78–89 years), annual thymalin courses were associated with significantly lower mortality and improved immune parameters vs. controls. Proposed mechanisms include telomerase activation in immune cells and restoration of thymic epithelial cell function.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.